Blog
RSS FeedPosted by Michael Wonder on 17 Apr 2023
ICER publishes final evidence report on lecanemab for Alzheimer’s disease
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
Posted by Michael Wonder on 14 Apr 2023
Throwing the baby out with the bath water: Congress considers banning the QALY
3 April 2023 - In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health ...
Posted by Michael Wonder on 13 Apr 2023
ICER publishes evidence report on treatments for non-alcoholic steatohepatitis
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
Posted by Michael Wonder on 11 Apr 2023
ICER publishes 2023 research protocol for assessing unsupported price increases on prescription drugs
11 April 2023 - Annual unsupported price increase report to be published on December 12. ...
Posted by Michael Wonder on 16 Mar 2023
ICER publishes white paper on using comparative effectiveness research to address prescription drug spending in California
16 March 2023 - State policy makers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research ...
Posted by Michael Wonder on 15 Mar 2023
ICER publishes white paper recommending health technology assessment methods that support health equity
15 March 2023 - Informed by expert advisory group and input from external stakeholders, white paper highlights on-going need to ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 11 Mar 2023
Drug pricing throughout the product lifecycle: a work in progress
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
Posted by Michael Wonder on 16 Feb 2023
ICER releases draft evidence report on treatments for non-alcoholic steatohepatitis
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
Posted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 17 Jan 2023
ICER publishes second annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
17 January 2023 - During ICER’s assessment, five payers revised policies for 11 medicines in ways that bring coverage into ...
Posted by Michael Wonder on 22 Dec 2022
ICER releases draft evidence report on treatments for Alzheimer’s disease
22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...
Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...